Introduction
429-437) [8] . Several HLA-B*13-associated mutations observed at CS p7/p1 indicate a strong selection pressure by HLA-B*13-restricted CTL [9] . The HIV-1 p7/ p1 CS mutations 436R, 437M and 437L were found to decrease CTL recognition of RI9 [8, 10] . Previously, the CS mutation 436R was found to accumulate in PIresistant HIV-1 isolates [11, 12] indicating that there might be interactions between the development of PI resistance and HLA-B*13-restricted immune responses. Although the HIV-1 CS mutation 431V is widely recognized as one of the major treatment-associated CS mutations in PI-resistant HIV-1 isolates [11] , the CS mutation 431V is observed with a frequency of 0.4% also in treatment-naive HIV-1 isolates without primary PR or reverse transcriptase (RT) resistance mutations [12] . So far, it is not known whether CS mutation 431V has an influence on CTL recognition and whether HLA-B*13-restricted CTL responses contribute to the selection of the 431V mutation in HIV-1-infected drugnaive patients.
Methods
We examined the effect of the 431V and 436R mutations on CTL recognition in nine HLA-B*13-positive patients of the Erlangen HIV cohort. Bulk sequencing of the CS p7/p1 revealed wild-type (WT) sequences in four patients, whereas CS mutations at aa positions 436 or 437 were detected in five cases (Figure 1 ). Freshly isolated peripheral blood mononuclear cells (PBMCs) or T-cell lines generated by stimulation of PBMC with peptide RI9 were analysed in interferon (IFN)-γ ELIS-POT assays for the recognition of RI9 and RI9 variants (WT: RQANFLGKI; 436R: RQANFLGRI; and 431V: RQVNFLGKI) using serial peptide dilutions. Treatment-naive HIV-1 isolates, which were obtained before the start of antiretroviral therapy in the RESINA study [13] , harbouring either CS mutation 431V in the absence of PR resistance mutations (n=4) or with primary drug resistance mutations according to the Shafer score [14, 15] (n=58), were identified. Primary PI resistance mutations were detected in 21 HIV-1 isolates (n=11 isolates with PR mutations only and n=10 isolates with both PR and RT mutations), and primary reverse transcriptase inhibitor (RTI) resistance mutations without any PI resistance mutations were observed in 37 cases. All patients were genotyped for HLA class I molecules (HLA-A and HLA-B).
Results
The ELISPOT assays in the nine HLA-B*13-positive patients showed diverse patterns regarding CTL recognition of the RI9 variants (WT, 431V and 436R; Figure 1) . Patients 1 and 2 recognized all RI9 variants at almost comparable activity. In patients 3 and 4, the 431V mutation abrogated and the 436R mutation slightly reduced the RI9-specific CTL response. Patient 5 showed a moderately reduced recognition of the 431V and 436R peptides in comparison to the WT peptide. In patient 7, the 436R mutation strongly decreased CTL recognition, whereas the 431V had only a slight attenuating effect. PBMCs from patient 6 failed to recognize WT and the 431V variant, but they specifically targeted the 436R variant. Interestingly, three (patients 6, 8 and 9) out of four patients carrying the 436R variant showed a better recognition of the 436R variant in comparison to the WT peptide, whereas the 436R mutation abrogated recognition in patient 7, whose predominant virus showed a WT RI9 sequence.
None of the patients infected with HIV-1 carrying CS mutation 431V without the presence of primary PI resistance mutations was HLA-B*13-positive (Table 1) . One patient carried the HLA-B*40 allele known to present the epitope TERQANFL (aa 427-434; an epitope comprising aa 431). Three patients were positive for HLA-A*02, which is known to present the epitope FLGKIWPSYK, spanning aa 433-442.
Some HIV-1 isolates of the RESINA study with primary PI resistance and/or RTI resistance additionally carried HIV-1 CS mutations 436R (n=6) and 431V (n=6; Table 2 ). In HIV-1 with primary PI resistance (n=21), CS mutations 431V and 436R were observed in 4 and 2 isolates, respectively. These mutations were detected in combination with different PR mutation patterns ( . HIV-1 isolates with primary RTI resistance (n=37) carried the CS mutation 436R in four cases and the 431V mutation in two cases. HLA-B*13 was only found once among the group of patients infected with HIV-1 isolates harbouring primary PI resistance mutations and twice in viruses harbouring RTI resistance mutations. HLA-B*40 was detected at similar frequencies in both groups. Neither 431V nor 436R HIV-1 CS mutations were correlated with HLA-B*13, HLA-B*40 or HLA-A*02 in these treatment-naive patients with primary HIV-1 drug resistance.
Discussion
HIV-1 CS mutations 431V and 436R can influence CTL recognition of HLA-B*13-positive chronically HIV-1-infected patients. The CTL response showed different patterns regarding the recognition of the 431V and 436R mutations indicating that there is a diverse T-cell receptor repertoire targeting the RI9 epitope. It has already been shown that HLA-B*13 preferentially selects for CS mutation 436R in treatment-naive HIV-1 isolates [8, 10] . Interestingly, although the 436R mutation could decrease recognition of RI9-specific CTL in subgroups of patients in our study, all three patients whose viral strain carried the 436R mutation better recognized the CS mutation 436R as the WT peptide. We do not know whether these patients had already been infected with an HIV-1 variant containing the 436R mutation or whether their HIV-1 strains have developed the 436R variant after infection by immune selection. In any case, this demonstrates that the CTL response in HLA-B*13 patients can adapt to mutations within CTL epitopes provided the anchor positions of the epitope are not affected. This is the first report showing that CS mutation 431V can influence CTL recognition of RI9-specific CTL, although there was no evidence that HLA-B*13 also contributes to the development of the CS mutation 431V mutation in treatment-naive patients. This is in accordance with previous studies that failed to detect the 431V mutation in treatment-naive HIV-1 isolates from 45 HLA-B*13-positive patients [8, 10] . The lack of immune selection of the 431V mutation could indicate that there are fitness costs by this mutation, counteracting CTL mediated immune selection in the absence of antiretroviral therapy. Myint et al. [16] showed that the 431V might actually decrease viral replication when inserted into a WT backbone. In contrast to that study, Nijhuis et al. [17] reported no obvious replication defect of 431V introduced in an HXB2 backbone, although one of five viruses solely carrying 431V acquired a further CS mutation in evolution experiments in the absence of PI pressure [18] . Recombinant viruses derived from full gag genes of PI-resistant HIV-1 isolates introduced in a WT backbone revealed replication capacities between 30-160% in comparison to a reference virus [1, 2] . Therefore, it seems most likely that sequence variation in Gag and PR determines the replicative capacity of 431V variants [19] . Even if fitness costs should prevent the outgrowth of CTL-selected 431V variants in untreated patients, we hypothesize that strong CTL pressure could generate 431V-carrying minority populations and might influence the development of drug resistance. Primary drug resistance of treatment-naive HIV-1 isolates can be observed because of the transmission of HIV-1 isolates, especially from treatment-experienced patients already harbouring drug resistance mutations. The same can happen with the CS mutations 431V and 436R, as both mutations accumulate in PI-resistant HIV-1 isolates while failing antiretroviral therapy [11] . The transmission of HIV-1 isolates harbouring these CS mutations to HLA-B*13-positive individuals might favour their maintenance of the CS mutations if they confer immune escape for RI9-specific CTL in these patients. It is conceivable that CTL-mediated preservation of CS mutations could favour the maintenance of transmitted PI resistance mutations, and in this case a higher frequency of HLA-B*13, HLA-B*40 or HLA-A*02 might be observed in this group of patients. In our study, patients with primary PIresistant HIV-1 isolates showed no significant increase in the frequencies of either HLA-B*13, HLA-A*02 or HLA-B*40. Moreover, in these drug-resistant HIV-1 isolates, neither HLA-B*13, HLA-B*40 nor HLA-A*02 were significantly correlated with the presence of CS mutations 436R or 431V. Although three out of four patients with a 431V mutation were HLA-A*02-positive, this frequency was not significantly different to the HLA-A*02 allele frequencies of the primary PI-resistant group (12/21) or the RTI-only resistant group (12/37; Fisher's exact test P>0.1). As the HLA-A*02-restricted CTL epitope FLGKIWPSYK (FK10, aa 433-442) is located two aa downstream from 431V, a direct influence of 431V on the recognition of the FK10 epitope does not seem to be likely; however, an influence of 431V on the processing of FK10 cannot be excluded.
On the basis of our observations, we speculate that the maintenance of CS mutation 431V by HIV-1 isolates from treatment-naive patients depends on compensatory fixation rather than on immune escape. This might also hold true for CS mutation 436R, explaining the lack of correlation between this CS mutation and HLA-B*13 in these primary drug-resistant HIV-1 isolates.
In summary, athough the 431V mutation can impair recognition by HLA-B*13-restricted CTL, we could not find any evidence that the prevalence of 431V in treatment-naive HIV-1 isolates is driven by immune selection of HLA-B*13-restricted CTL. Moreover, the prevalence of HLA-B*13 in the Caucasian population (approximately 7%) and frequencies of CS mutation 431V of <1% in treatment-naive and of >40% in PI-resistant HIV-1 isolates do not suggest a major effect of HLA-B*13 for the selection of CS mutation 431V [11, 12] . The presence of treatment-associated CS mutations in treatment-naive HIV-1-isolates might rather indicate the transmission of PI-resistant HIV-1 isolates than natural sequence variability. Nevertheless, in individual patients, immune escape and evolution of drug resistance might go hand in hand. Further long-term studies are needed to evaluate the clinical effect of HIV-1 CS mutation 431V in treatment-naive patients. 
